Acute Lymphoblastic Leukemia Therapeutics Market Outlook 2031
The acute lymphoblastic leukemia therapeutics market size was USD 2.37 Billion in 2022 and anticipated to reach USD 4.58 Billion by 2031 expand at a CAGR of 7.6 % during the forecast period, 2023-2031. The growth of the market is attributed to the rising occurrence of acute lymphoblastic leukemia (ALL) globally.
ALL is a type of blood cancer that develops from immature germination of lymphocytes. The incidence of the cancer is higher in children from 0 to 14 years than in those aged 15 years and above. Some of the symptoms of the cancer are bone pain, bleeding from the gums, pale skin, and fatigue.
Acute Lymphoblastic Leukemia Therapeutics Market Drivers, Restraints, Trends, and Opportunities
- Improvement in the healthcare insurance plans and increasing investment in the healthcare infrastructure are expected to propel the market growth.
- High cost of therapies can restrain the acute lymphocytic leukemia therapeutics market
- The COVID-19 pandemic had increased the burden on the healthcare sector. However, the market is anticipated to recover soon.
- Increasing investment on the R&D activities, government initiatives to support the research, and rising number of support grants are expected to proliferate the market growth.
Scope of Acute Lymphoblastic Leukemia Therapeutics Market Report
The report on acute lymphoblastic leukemia therapeutics market includes an assessment of the market, trends, segments and regional markets. Overview and dynamics have also been included in the report.
|
Attributes
|
Details
|
|
Report Title
|
Acute Lymphoblastic Leukemia Therapeutics Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast
|
|
Base Year
|
2022
|
|
Historic Data
|
2016–2021
|
|
Forecast Period
|
2023–2031
|
|
Segmentation
|
Type of Cells [B-cell ALL, T-cell ALL, Philadelphia Chromosome: Positive (Ph+) and Negative (Ph-) ALL], Type of Therapies (Chemotherapy [Hyper – CVAD Regimen, CALGB 8811 Regimen, Linker Regimen, Nucleoside Inhibitors, and Others], Targeted Therapy, Radiation Therapy, and Stem Cell Transplantation)
|
|
Regional Scope
|
Europe, Asia Pacific, Middle East & Africa, South America
|
|
Report Coverage
|
Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast
|
|
Key Players Covered in the Report
|
Pfizer Inc., Bristol-Myers Squibb Company, Novartis AG, SymBio Pharmaceuticals Limited, and Genmab AS
|
Acute Lymphoblastic Leukemia Therapeutics Market Segment Insights
B-cell ALL segment to account a significant market share
On the basis of type of cells, the market is segregated into B-cell ALL, T-cell ALL, Philadelphia Chromosome: Positive (Ph+) and Negative (Ph-) ALL. The B-cell ALL segment to account for a significant market share during the forecast period. On the other hand, the T-cell ALL segment to grow at a healthy rate during the forecast period.
Chemotherapy segment to dominate the market
Based on type of therapies, the market is divided as chemotherapy, targeted therapy, radiation therapy, and stem cell transplantation. The chemotherapy segment is further divided into hyper – CVAD regimen, CALGB 8811 regimen, linker regimen, nucleoside inhibitors, and others. The chemotherapy segment is projected to dominate the market during the forecast period owing to increased incidence of leukemia globally.
The American Cancer Association stated that chemotherapy is the one of the crucial treatments for the people suffering from ALL. Chemotherapy uses cytotoxic drugs for the destruction of cancer cells. Amsacrine, cyclophosphamide and cytarabine are some of the drugs that are used for chemotherapy treatment. Global pharmaceutical players, such as Baxter International, and Pfizer, are major suppliers of these drugs.
North America to account a major market share
Based on regions, the market is divided into Europe, Asia Pacific, Middle East & Africa, and South America. North America is projected to account for a major market share during the forecast period. The regional market growth is attributed to the rising number of cases of this disease in the region due to genetic factors, environmental factors, and radiation. Favorable government policies, well-established healthcare infrastructure, and the presence of multinational companies are driving the market growth in the region.
The market in Asia Pacific is expected to register a high CAGR during the forecast period owing to several factors, such as high unmet clinical needs, large patient pool, and the rising awareness about early diagnosis in emerging countries.
Segments
Type of Cells
- B-cell ALL
- T-cell ALL
- Philadelphia Chromosome: Positive (Ph+) and Negative (Ph-) ALL]
Type of Therapy
- Chemotherapy
- Hyper – CVAD Regimen
- CALGB 8811 Regimen
- Linker Regimen
- Nucleoside Inhibitors
- Others
- Targeted Therapy
- Radiation Therapy
- Stem Cell Transplantation
Geography
- North America
- Europe
- Asia Pacific
- Middle East
- Middle East & Africa
- Latin America
Key players
Competitive Landscape
The market for acute lymphoblastic leukemia is moderately competitive and consists of the big players as well as the mid-sized companies. Some of the major players in the market are Pfizer Inc., Bristol-Myers Squibb Company, Novartis AG, SymBio Pharmaceuticals Limited, Genmab AS.
Major companies are focusing on the discovery of the drugs and are engaging in partnerships and medical universities to propel the development of drugs or treatments.
Request For Customization
Enquiry Before Buying
Speak With Analyst
